vimarsana.com
Home
Live Updates
Considerations When Deciding Between an IO/TKI and IO/IO Treatment Regimen for a Patient With RCC : vimarsana.com
Considerations When Deciding Between an IO/TKI and IO/IO Treatment Regimen for a Patient With RCC
Hans Hammers, MD, PhD, explains the situations in which he would choose an ipilimumab/nivolumab treatment regimen over one of the discussed IO/TKI regimens.
Related Keywords
,
New Wave
,
Renal Cell Carcinoma
,
Deciding Between
,
Patient With
,
Nrcc
,
Renal Cell Carcinoma Treatment
,
Asco Gu 2023
,
Asco Gu Rcc
,
Rcc Treatment
,
Clear Cell Rcc
,
Non Clear Cell Rcc
,
Imdc Risk
,
Intermediate Risk
,
Tumor Shrinkage
,
Dose Reduction
,
Mskcc Prognostic Model
,
vimarsana.com © 2020. All Rights Reserved.